Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2

Genes and Development

Volumn 19, Issue 15, 2005, Pages 1773-1778

  Manning, Brendan D ^a   Logsdon, M Nicole ^a   Lipovsky, Alex I ^a   Abbott, Derek ^b,c,d   Kwiatkowski, David J ^d   Cantley, Lewis C ^b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cowden disease; Forkhead; FOXO; Hamartoma syndromes; PKB; Tuberous sclerosis complex

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUBERIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEEDBACK SYSTEM; GENETIC ANALYSIS; HAPLOIDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; FEEDBACK; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORIC MONOESTER HYDROLASES; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 23744516268     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1314605     Document Type: Article

References (39)

1. Aoki, M., Blazek, E., and Vogt, P.K. 2001. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. 98: 136-141.
2. Cantley, L.C. and Neel, B.G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. 96: 4240-4245.
3. DiCristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P.P. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19: 348-355.
4. +/- mice. Science 285: 2122-2125.
5. DiCristofano, A., DeAcetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi, P.P. 2001. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27: 222-224.
6. El-Hashemite, N., Zhang, H., Henske, E.P., and Kwiatkowski, D.J. 2003. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 361: 1348-1349.
7. El-Hashemite, N., Walker, V., and Kwiatkowski, D.J. 2005. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: A tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res. 65: 2474-2481.
8. Eng, C. 2003. PTEN: One gene, many syndromes. Hum. Mutat. 22: 183-198.
9. Fingar, D.C. and Blenis, J. 2004. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171.
10. Goncharova, E.A., Goncharov, D.A., Eszterhas, A., Hunter, D.S., Glassberg, M.K., Yeung, R.S., Walker, C.L., Noonan, D., Kwiatkowski, D.J., Chou, M.M., et al. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277: 30958-30967.
11. Harrington, L.S., Findlay, G.M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N.R., Cheng, S., Shepherd, P.R., et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell. Biol. 166: 213-223.
12. Henske, E.P. 2005. Tuberous sclerosis and the kidney: From mesenchyme to epithelium, and beyond. Pediatr. Nephrol. 20: 854-857.
13. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.L. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol. 4: 648-657.
14. Kenerson, H.L., Aicher, L.D., True, L.D., and Yeung, R.S. 2002. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62: 5645-5650.
15. Kobayashi, T., Minowa, O., Kuno, J., Mitani, H., Hino, O., and Noda, T. 1999. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res. 59: 1206-1211.
16. Kwiatkowski, D.J. 2003. Tuberous sclerosis: From tubers to mTOR. Ann. Hum. Genet. 67: 87-96.
17. Kwiatkowski, D.J., Zhang, H., Bandura, J.L., Heiberger, K.M., Glogauer, M., El-Hashemite, N., and Onda, H. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and upregulation of p70S6 kinase activity in TSC1 null cells. Hum. Mol. Genet. 11: 525-534.
18. Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M.S., El-Hashemite, N., et al. 2005. Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42: 213-227.
19. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
20. Li, L., Liu, F., Salmonsen, R.A., Turner, T.K., Litofsky, N.S., Di Cristofano, A., Pandolfi, P.P., Jones, S.N., Recht, L.D., and Ross, A.H. 2002. PTEN in neural precursor cells: Regulation of migration, apoptosis, and proliferation. Mol. Cell Neurosci. 20: 21-29.
21. Ma, L., Teruya-Feldstein, J., Behrendt, N., Chen, Z., Noda, T., Hino, O., Cordon-Cardo, C., and Pandolfi, P.P. 2005. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes & Dev. (this issue).
22. Manning, B.D. 2004. Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. J. Cell. Biol. 167: 399-403.
23. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., and Cantley, L.C. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell 10: 151-162.
24. McManus, E.J., Collins, B.J., Ashby, P.R., Prescott, A.R., Murray-Tait, V., Armit, L.J., Arthur, J.S., and Alessi, D.R. 2004. The in vivo role of PtdIns(3,4,5)P(3) binding to PDK1 PH domain defined by knockin mutation. EMBO J. 23: 2071-2082.
25. Neshat, M.S., Mellinghoff, I.K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J.J., Wu, H., and Sawyers, C.L. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. 98: 10314-10319.
26. +/- mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104: 687-695.
27. Plas, D.R. and Thompson, C.B. 2003. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 278: 12361-12366.
28. Podsypanina, K., Ellenson, L.H., Nemes, A., Gu, J., Tamura, M., Yamada, K.M., Cordon-Cardo, C., Catoretti, G., Fisher, P.E., and Parsons, R. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. 96: 1563-1568.
29. +/- mice. Proc. Natl. Acad. Sci. 98: 10320-10325.
30. Potter, C.J., Pedraza, L.G., and Xu, T. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell. Biol. 4: 658-665.
31. Radimerski, T., Montagne, J., Hemmings-Mieszczak, M., and Thomas, G. 2002. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes & Dev. 16: 2627-2632.
32. Shah, O.J., Wang, Z., and Hunter, T. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival defects. Curr. Biol. 14: 1650-1656.
33. Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho, R.A., and Cantley, L.C. 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
34. Stambolic, V., Suzuki, A., delaPompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J.M., Sioderovski, D.P., and Mak, T.W. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
35. Sun, H., Lesche, R., Li, D., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., and Wu, H. 1999. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-triphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. 96: 6199-6204.
36. Suzuki, A., delaPompa, J.L., Stambolic, V., Elia, E.J., Sasaki, T., delBarco-Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W., et al. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8: 1169-1178.
37. Tran, H., Brunet, A., Griffith, E.C., and Greenberg, M.E. 2003. The many forks in FOXO's road. Sci. STKE 2003: RE5.
38. Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., and Lowe, S.W. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
39. Zhang, H., Cicchetti, G., Onda, H., Koon, H.B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C.L., and Kwiatkowski, D.J. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112: 1223-1233.